Life Sciences IP Litigation

Latham’s award-winning life sciences IP practice works at the cutting edge of pharmaceutical and biotechnology patent, trade secrets, and brand-on-brand competitor litigation.

Why Latham

We offer life sciences companies a deep bench of patent litigators, many of whom hold advanced degrees in chemical or life sciences, as well as a team of PhD-holding technical analysts and former Federal Circuit clerks with significant experience litigating pharmaceutical cases. Our representations of innovator companies begin with us analyzing client patents and mastering the underlying science. Our lawyers and analysts are well-versed in all forms of life sciences patent and trade secrets litigation, from brand-on-brand biologic disputes, to matters involving vaccines, biosimilars, CRISPR, CAR-T, gene therapy, and diagnostics and manufacturing processes.

Hatch-Waxman Litigation

We represent many of the world’s leading innovative pharmaceutical companies in Hatch-Waxman litigation, regularly enforcing and defending patents that protect products with billions of dollars in annual sales.

Patent challenges by generic drug manufacturers are a persistent issue for branded pharmaceutical companies. We bring extensive experience preparing for and defending against these challenges. We understand the strategic and tactical implications that are particular to Abbreviated New Drug Application (ANDA) cases and use this knowledge to protect clients’ market opportunities, including in relation to pre-suit investigations, FDA strategy and related litigation, Patent Office proceedings, District Court litigations, and appeals. We leverage our extensive ANDA litigation experience with to develop a case that accounts for multiple challengers presenting multiple theories.

Our Experience

Awards & Rankings

  • Latham Recognized Across the Board for Litigation & Trial Prowess - October 14, 2020
  • Latham Honored at the National Law Journal’s 2019 Professional Excellence Awards Ceremony - November 11, 2019
  • Silicon Valley Litigator Selected Among Top Trade Secrets Lawyers - October 14, 2019
  • Latham Named D.C. General Litigation Department of the Year Finalist - June 02, 2019
  • David Callahan Named Illinois Outstanding Intellectual Property Litigator of the Year - April 10, 2019

Latham is distinguished by its “strong profile for complex patent litigation,” “expertise in Hatch-Waxman proceedings.”

Chambers USA 2020

Media Coverage

Intellectual Property Group of the Year: LathamFed. Circ. Affirms Hospira's Generic Adrenalin Loss To ParPfizer generic epinephrine shot would infringe Endo patents - Fed Circuit

News

Two Leading Life Sciences IP Litigators Join Latham Latham Adds Prominent Life Sciences Patent LitigatorFirm Recognized for Breadth of Life Science Practice in 2012 Industry Guide

Thought Leadership

Strategic Implications of Recent Changes in PTAB ProceedingsPTAB Update: Patent Office Issues Final Pilot Program for Motions to Amend Supreme Court Says a Secret Sale Qualifies as Prior Art Under AIA